Pioneering research is paving the way for the possibility of preventing rheumatoid arthritis, a debilitating autoimmune condition that affects millions worldwide. Researchers have identified blood markers, such as anti-cyclic citrullinated peptide antibodies, that can help detect those at risk of the disease long before the onset of joint inflammation and other symptoms.
The preclinical stage of rheumatoid arthritis, which can last for several years, is now better understood, allowing healthcare providers to identify individuals who are susceptible to the condition but may not yet exhibit outward signs. This early detection opens up the potential for targeted interventions to delay or even prevent the full-blown development of the disease.
“Rheumatoid arthritis has a preclinical stage of development, a time about three to five years or longer, prior to the onset of swollen joints when markers like rheumatoid factor and anti-cyclic citrullinated peptide are detectable in the blood,” explains Professor Kevin Deane, a physician specialising in rheumatoid arthritis and a researcher who has conducted clinical trials on treatments for the condition.
Trials have been conducted on individuals who test positive for these biomarkers or have other risk factors, such as joint pain and subclinical joint inflammation. These studies have primarily focused on using immune-modulating drugs commonly used to treat established rheumatoid arthritis, such as methotrexate, hydroxychloroquine, and rituximab, to see if a short course of treatment could lead to a lasting reset of the immune system and prevent the disease from fully manifesting.
While there is not yet an approved drug for rheumatoid arthritis prevention, these studies offer hope that researchers are on the right track to finding the appropriate drug, dosage, and duration to effectively target the underlying immune system abnormalities that drive the development of the disease.
Challenges remain, however, as researchers work to better understand the biology of the preclinical stage and improve their ability to accurately predict which individuals will go on to develop full-blown rheumatoid arthritis. The “mucosal origins” hypothesis, which suggests that early autoimmunity in rheumatoid arthritis may be triggered by inflammation at mucosal surfaces like the gums, lungs, and gut, offers a promising avenue for future research and interventions.
As the field advances, the goal is to integrate routine testing for rheumatoid arthritis risk factors into standard healthcare, much like how cardiovascular disease risk is assessed through cholesterol measurements. This could lead to significant changes in the management of rheumatoid arthritis, potentially allowing for the prevention or delay of the debilitating effects of this condition in the years to come.